Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Hemoglobin01:24

Hemoglobin

8.8K
Hemoglobin is a globular protein made up of four subunits. Two of these subunits are alpha chains, and the other two are beta chains. Each subunit contains a molecule of heme, which has an iron atom and can bind to oxygen. When an oxygen molecule binds to one heme group, it changes the shape of hemoglobin, making it easier for the other heme groups to bind oxygen as well.
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...
8.8K
Rh Blood Group01:19

Rh Blood Group

4.4K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
4.4K
Introduction to Hemostasis01:05

Introduction to Hemostasis

14.3K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
14.3K
X-linked Traits01:19

X-linked Traits

45.7K
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
45.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utility of a Digital PCR-Based Gene Expression Panel for Detection of Leukemic Cells in Pediatric Acute Lymphoblastic Leukemia.

International journal of molecular sciences·2026
Same author

Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review.

Hematology, transfusion and cell therapy·2024
Same author

Salud publica de Mexico·2023
Same author

Anti-phosphatidylserine/prothrombin antibodies in patients with polyarteritis nodosa.

Reumatologia clinica·2021
Same author

Anti-Phosphatidylserine/Prothrombin antibodies in patients with Polyarteritis Nodosa.

Reumatologia clinica·2020
Same author

Acute Myeloid Leukemia in Mexico: The Specific Challenges of a Developing Country. Results From a Multicenter National Registry.

Clinical lymphoma, myeloma & leukemia·2020
Same journal

[Clinical activity and validation of the disability disc in inflammatory bowel disease].

Revista medica del Instituto Mexicano del Seguro Social·2026
Same journal

[Ischemic Priapism: evaluation in a third-level hospital in Mexico].

Revista medica del Instituto Mexicano del Seguro Social·2026
Same journal

[Visual field index and pituitary tumors resected by microsurgical transsphenoidal approach].

Revista medica del Instituto Mexicano del Seguro Social·2026
Same journal

[Clinical and obstetric characteristics in women with multiple sclerosis during pregnancy].

Revista medica del Instituto Mexicano del Seguro Social·2026
Same journal

[Breast MRI: Kaiser score agreement with and without diffusion].

Revista medica del Instituto Mexicano del Seguro Social·2026
Same journal

[High diagnostic discrepancy in infectious diseases detected by autopsy].

Revista medica del Instituto Mexicano del Seguro Social·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.0K

[Hemophilia.]

Lauro Fabián Amador-Medina1, Angel Gabriel Vargas-Ruiz

  • 1Departamento de Hematología y Oncología, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán," Secretaría de Salud, Distrito Federal, México. lafab81@hotmail.com.

Revista Medica Del Instituto Mexicano Del Seguro Social
|December 3, 2013
PubMed
Summary
This summary is machine-generated.

Hemophilia, a genetic bleeding disorder, involves deficiencies in factor VIII (hemophilia A) or IX (hemophilia B). Diagnosis requires measuring clotting factor levels, with treatment involving factor replacement therapy.

Keywords:
factor IXfactor IXfactor VIIIhemofiliahemophiliahemorragiahemorrhage

More Related Videos

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

14.3K
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

191

Related Experiment Videos

Last Updated: May 5, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.0K
Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

14.3K
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

191

Area of Science:

  • Hematology
  • Genetics
  • Internal Medicine

Background:

  • Hemophilia is an inherited bleeding disorder characterized by hemorrhage.
  • It presents as hemophilia A (factor VIII deficiency) or hemophilia B (factor IX deficiency).
  • Bleeding severity correlates with plasma levels of factors VIII or IX, categorized as mild, moderate, or severe.

Purpose of the Study:

  • To summarize the understanding of hemophilia A and B.
  • To outline diagnostic methods and current treatments.
  • To mention potential future therapies and complications.

Main Methods:

  • Review of hemophilia A and B characteristics.
  • Description of diagnostic laboratory tests, including activated partial thromboplastin time (aPTT).
  • Explanation of current treatment modalities and potential complications.

Main Results:

  • Hemophilia A and B are distinguished by deficiencies in specific clotting factors.
  • Diagnosis relies on quantifying factor VIII or IX levels, as aPTT may be isolatedly prolonged.
  • Treatment involves administering exogenous factor concentrates.

Conclusions:

  • Hemophilia A and B are genetic bleeding disorders requiring specific factor level assessment for diagnosis.
  • Current management focuses on factor replacement therapy.
  • Gene therapy offers future curative potential, while complications like inhibitors and arthropathy require ongoing attention.